Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

The prognostic value of reactive stroma on prostate needle biopsy: a population-based study.

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U.

Prostate. 2015 May;75(6):662-71. doi: 10.1002/pros.22957. Epub 2015 Jan 25.

PMID:
25620661
2.

Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: A single-centre experience.

Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K.

Scand J Urol. 2015 Jun;49(3):218-23. doi: 10.3109/21681805.2014.982168. Epub 2014 Nov 27.

PMID:
25428750
3.

The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy.

Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K.

Urol Int. 2014;93(3):289-95. doi: 10.1159/000362342. Epub 2014 Aug 27. Review.

PMID:
25170745
4.

SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas.

Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z.

PLoS One. 2013 Jul 30;8(7):e70558. doi: 10.1371/journal.pone.0070558. Print 2013.

5.

Dendritic and lymphocytic cell infiltration in prostate carcinoma.

Liu Y, Sæter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K.

Histol Histopathol. 2013 Dec;28(12):1621-8. Epub 2013 Jun 3.

PMID:
23729368
6.

Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?

Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, Axcrona K.

Int J Urol. 2012 Aug;19(8):749-56. doi: 10.1111/j.1442-2042.2012.03017.x. Epub 2012 Apr 4.

PMID:
22487487
7.

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group.

Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.

PMID:
22189383
8.

Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer.

Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, Axcrona K, Beisland HO.

BJU Int. 2012 May;109(10):1489-94. doi: 10.1111/j.1464-410X.2011.10583.x. Epub 2011 Sep 20.

PMID:
21933333
9.

The cost of hemiarthroplasty compared to that of internal fixation for femoral neck fractures. 2-year results involving 222 patients based on a randomized controlled trial.

Frihagen F, Waaler GM, Madsen JE, Nordsletten L, Aspaas S, Aas E.

Acta Orthop. 2010 Aug;81(4):446-52. doi: 10.3109/17453674.2010.492763.

10.

Does a tertiary Gleason pattern 4 or 5 influence the risk of biochemical relapse after radical prostatectomy for clinically localized prostate cancer?

Servoll E, Saeter T, Vlatkovic L, Nesland J, Waaler G, Beisland HO.

Scand J Urol Nephrol. 2010 Sep;44(4):217-22. doi: 10.3109/00365591003720283.

PMID:
20367396
11.

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.

Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fosså S, Widmark A; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3.

Lancet Oncol. 2009 Apr;10(4):370-80. doi: 10.1016/S1470-2045(09)70027-0. Epub 2009 Mar 13.

PMID:
19286422
12.

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3.

Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Erratum in: Lancet. 2009 Apr 4;373(9670):1174.

13.

How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?

Fosså SD, Jacobsen AB, Aass N, Heilo A, Stenwig AE, Kummen O, Johannessen NB, Waaler G, Ogreid P, Borge L, et al.

Br J Cancer. 1994 Dec;70(6):1156-60.

14.
15.

Prognosis of localised prostatic cancer managed by "watch and wait" policy.

Waaler G, Stenwig AE.

Br J Urol. 1993 Aug;72(2):214-9.

PMID:
8402025
16.

Prostatic cancer in Aust-Agder County, Norway. Age, stage, grade and mode of presentation.

Waaler G, Ludvigsen TC.

Scand J Urol Nephrol. 1991;25(2):107-10.

PMID:
1871553
17.

Prognosis of incidental prostatic cancer in Aust-Agder County, Norway.

Waaler G, Ludvigsen TC, Stenwig AE.

Eur Urol. 1990;18(3):179-83.

PMID:
1702057
18.

[Tetracycline sclerotherapy in hydrocele and epididymal cysts].

Baksaas ST, Beisland HO, Waaler G.

Tidsskr Nor Laegeforen. 1988 May 20;108(14):1134-5. Norwegian. No abstract available.

PMID:
3291189
19.

[Digital rectal exploration as a screening for prostatic cancer].

Stenehjem E, Ludvigsen TC, Rundén TO, Waaler G, Ogreid PI, Schei OM.

Tidsskr Nor Laegeforen. 1988 Mar 20;108(8-9):674-5. Norwegian. No abstract available.

PMID:
3353969
20.

Digital rectal examination to screen for prostatic cancer.

Waaler G, Ludvigsen TC, Runden TO, Stenehjem E, Ogreid P, Schei OM.

Eur Urol. 1988;15(1-2):34-6.

PMID:
3215234
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk